Introduction: Limited information is available on the burden of multimorbidity among diabetics in India.

Methods: We conducted a cross-sectional study among 12284 adults aged ≥ 30 years, using multistage cluster random sampling, from rural and urban areas of North and South India. Trained interviewers administered a questionnaire to collect data on socio-demographics, lifestyle characteristics and collected blood samples. We defined diabetes, hypertension, and their control as per standard definitions; dyslipidemia as per ATP IV or on treatment; CKD as those on treatment or with urine albumin-creatinine ≥30 mg/g or eGFR <60 ml/min/1.73 m2; central obesity as waist circumference ≥ 90 cm (men) and ≥ 80 cm (women); heart disease and stroke per self-reported physician diagnosis or treatment. Multivariable logistic regression was conducted to determine factors independently associated with multimorbidity.

Results: The age-adjusted prevalence of diabetes was [17.5%, 95% CI (16.9-18.2)], 56.1% (54.5-57.6) were aware and 86.8% (85.3-88.2) were taking antidiabetic treatment. The prevalence of multimorbidity was higher among diabetics [hypertension: 55.1% (53.1-57.2), central obesity: 72.9% (71.0-74.8), dyslipidemia: 74.4% (72.5-76.2), CKD: 8.8% (8.7-8.9), heart disease: 5.5% (4.6-6.5), stroke: 2.0% (1.5-2.9)] compared to nondiabetics [hypertension: 31.1% (30.1-34.7), central obesity: 53.2% (52.5-53.8), dyslipidemia: 51.2% (50.6-51.6), CKD: 5.9% (5.6-6.2), heart disease: 2.2% (2.0-2.4), stroke: 1.1% (1.0-1.2)]. Increasing age, poor education [adjusted odds ratio (aOR): 1.7 (1.1-2.6)], richest [aOR: 2.1 (1.2-3.5)] and urban residents [aOR: 1.5 (1.1-2.0)] were more likely to have at least one multimorbidity. Those taking anti-diabetic treatment were less likely to have multimorbidity [aOR: 0.7 (0.5-0.9)].

Conclusions: High levels of multimorbidity in India warrants implementation of effective health system interventions for integrated management of diabetes and multimorbidity to improve outcomes.

Disclosure

S. Mohan: None. P. Jarhyan: None. M. Dubey: None. N. Srinivasapura Venkateshmurthy: None. D. Prabhakaran: None.

Funding

An unrestricted grant under the Lilly NCD Partnership programme.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.